Clinical trial · Interventional
68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma
Comparison of 68Ga-pentixather and 68Ga-pentixafor PET/CT in Patients With Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Chemokine receptor-4 (CXCR4) is overexpressed in multiple myeloma (MM) cells. 68Ga-pentixafor is a radio-labled tracer for CXCR4 . 68Ga-pentixafor PET/CT has shown good diagnostic performance in MM. But an exchange of Ga3+ by Lu3+ or Y3+ will lead to a significant loss of CXCR4 affinity. Investigators conduct this prospective study to evaluate the diagnostic performance of 68Ga-pentixather compared with 68Ga-pentixafor, in order to parallel 68Ga-pentixather and 177Lu/90Y-pentixather in theranostics of MM.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-Pentixafor | Drug | — | UNRESOLVED |
| 68Ga-Pentixather | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT scan
- description
- Participants with multiple myeloma will perform 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT within 7-day interval
- interventionNames
- Drug: 68Ga-Pentixather
- Drug: 68Ga-Pentixafor
Primary outcomes (4)
- measure
- Metabolic parameter
- timeFrame
- through study completion, an average of 2 years
- description
- Comparison of metabolic parameter (SUVmax) between 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT.
- measure
- PET-positive diffuse bone marrow involvement
- timeFrame
- through study completion, an average of 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Suspected or confirmed untreated multiple myeloma (MM), relapsed MM, MM in remission 2. Signed written consent Exclusion Criteria: 1. pregnancy 2. breastfeeding 3. known allergy against pentixather or pentixafor 4. any medical condition that in the opinion of the investigator, may significantly interfere with study compliance.
References
Publications (0)
Data not yet available